Biodesix Inc (NASDAQ:BDSX) — Market Cap & Net Worth
Market Cap & Net Worth: Biodesix Inc (BDSX)
Biodesix Inc (NASDAQ:BDSX) has a market capitalization of $79.44 Million ($79.44 Million) as of June 17, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #20175 globally and #4522 in its home market, demonstrating a 2.54% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Biodesix Inc's stock price $15.33 by its total outstanding shares 7955685 (7.96 Million). Review how much debt does Biodesix Inc carry to assess the company's total debt and financial obligations.
Biodesix Inc Market Cap History: 2020 to 2026
Biodesix Inc's market capitalization history from 2020 to 2026. Data shows growth from $160.39 Million to $121.96 Million (3.24% CAGR).
Index Memberships
Biodesix Inc is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.43 Trillion | 0.00% | #571 of 976 |
|
NASDAQ Composite
IXIC
|
$41.27 Trillion | 0.00% | #1944 of 3165 |
Weight: Biodesix Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Biodesix Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Biodesix Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.17x
Biodesix Inc's market cap is 0.17 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2020 | $160.39 Million | $45.56 Million | -$31.35 Million | 3.52x | N/A |
| 2021 | $42.09 Million | $54.51 Million | -$43.16 Million | 0.77x | N/A |
| 2022 | $18.30 Million | $38.21 Million | -$65.45 Million | 0.48x | N/A |
| 2023 | $14.64 Million | $49.09 Million | -$52.15 Million | 0.30x | N/A |
| 2024 | $12.17 Million | $71.32 Million | -$42.93 Million | 0.17x | N/A |
Competitor Companies of BDSX by Market Capitalization
Companies near Biodesix Inc in the global market cap rankings as of June 17, 2026.
Key companies related to Biodesix Inc by market ranking:
- Thermo Fisher Scientific Inc (NYSE:TMO): Ranked #127 globally with a market cap of $177.57 Billion USD.
- Danaher Corporation (NYSE:DHR): Ranked #182 globally with a market cap of $128.10 Billion USD.
- IDEXX Laboratories Inc (NASDAQ:IDXX): Ranked #626 globally with a market cap of $44.18 Billion USD.
- LONZA GROUP UNSP.ADR 1/10 (F:LO3A): Ranked #663 globally with a market cap of $41.04 Billion USD ( €35.10 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #127 | Thermo Fisher Scientific Inc | NYSE:TMO | $177.57 Billion | $472.63 |
| #182 | Danaher Corporation | NYSE:DHR | $128.10 Billion | $181.35 |
| #626 | IDEXX Laboratories Inc | NASDAQ:IDXX | $44.18 Billion | $573.00 |
| #663 | LONZA GROUP UNSP.ADR 1/10 | F:LO3A | $41.04 Billion | €54.50 |
Biodesix Inc Historical Marketcap From 2020 to 2026
Between 2020 and today, Biodesix Inc's market cap moved from $160.39 Million to $ 121.96 Million, with a yearly change of 3.24%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $121.96 Million | +125.44% |
| 2025 | $54.10 Million | +344.44% |
| 2024 | $12.17 Million | -16.85% |
| 2023 | $14.64 Million | -20.00% |
| 2022 | $18.30 Million | -56.52% |
| 2021 | $42.09 Million | -73.76% |
| 2020 | $160.39 Million | -- |
End of Day Market Cap According to Different Sources
On Jun 17th, 2026 the market cap of Biodesix Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $79.44 Million USD |
| MoneyControl | $79.44 Million USD |
| MarketWatch | $79.44 Million USD |
| marketcap.company | $79.44 Million USD |
| Reuters | $79.44 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Biodesix Inc
Biodesix, Inc. operates as a diagnostic solutions company. The company offers blood-based lung tests, including Nodify XL2 and Nodify CDT tests markets as Nodify Lung Nodule Risk Assessment testing to assess the risk of lung cancer and help in identifying the appropriate treatment pathway and help physicians in reclassifying risk of malignancy in patients with suspicious lung nodules. It also pro… Read more